Selectivity begins when an IR700-containing photosensitizer is linked to an antibody that recognizes a particular cell-surface antigen. Binding concentrates the photosensitizer on antigen-bearing cells before illumination. Near 690 nm, laser activation then produces photochemical changes that disrupt the membrane and cause rapid cell death, while cells lacking the recognized antigen are less directly targeted.
The Ir700 dye laser supplies light near 690 nm, the illumination range identified for triggering photochemical changes in IR700. Those changes are central to membrane disruption and rapid cell death after the antibody-linked photosensitizer has bound its target. Thus, the light wavelength connects the optical treatment step to the biological action of the targeted photosensitizer.
The targeting strategy ties photosensitizer activity to recognition of a specific cell-surface antigen rather than exposing cells without a targeting step. Antibody binding helps concentrate IR700 on antigen-bearing tumor cells, so subsequent illumination can produce a more selective response. This distinction supports investigations of precision oncology and helps explain why surrounding tissue exposure may be limited.
Two central requirements are accurate targeting and controlled light delivery. The antibody-linked IR700 photosensitizer must bind the intended cell-surface antigen, and illumination near 690 nm must be directed under defined experimental conditions. Researchers also need to evaluate safety and therapeutic efficacy, because selective targeting and light exposure together determine how the treatment response is interpreted.
The system supports studies of targeted cancer treatment, precision oncology, and targeted drug delivery. It can also be used to investigate immune-mediated treatment responses after selective tumor-cell damage. These applications allow researchers to examine how antigen-directed photosensitizer activation may connect localized light treatment with broader biological responses in biomedical research.
Researchers can assess whether antigen-bearing tumor cells undergo the expected rapid cell death following illumination and whether surrounding tissue remains comparatively less affected. They can also examine immune-mediated treatment responses and evaluate safety and therapeutic efficacy. These outcomes are important for determining whether accurate targeting and controlled light delivery produce a useful and reproducible treatment response.